The Female Health Company / Veru Healthcare to Report Fiscal 2017 Second-Quarter Financial Results, Host Conference Call on Tuesday, May 9

MIAMI, May 02, 2017 -- The Female Health Company / Veru Healthcare (NASDAQ:FHCO) today announced that it will report financial results for its fiscal 2017 second quarter on Tuesday, May 9, 2017, before the market opens.  The company’s management will host a conference call the same day at 8 a.m. Eastern Time to review the company’s performance and answer questions.

The conference call will be available to interested parties by dialing 1-877-883-0383 from the U.S. or 1-412-902-6506 from international locations, participant entry number for all of 8584665.

A replay of the conference call will be available beginning within a few hours of the live conference call on Tuesday, May 9, 2017 through Tuesday, May 16, 2017, by dialing 1-877-344-7529 for US callers (international callers dial 1-412-317-0088) and entering the replay access code 10106205.  After Tuesday, May 16, 2017, the replay of the call will be available on the Company’s website at https://veruhealthcare.com/investors.

About The Female Health Company / Veru Healthcare
The Female Health Company / Veru Healthcare is a pharmaceutical and medical device company, with a focus on the development and commercialization of pharmaceuticals that qualify for the FDA's 505(b)(2) accelerated regulatory approval pathway as well as the 505(b)(1) pathway.  The Company does business both as "Veru Healthcare" and as "The Female Health Company" and is organized as follows:

• Veru Healthcare manages the Pharmaceuticals Division, which develops and commercializes pharmaceutical products for men's and women's health and oncology.
   
• Veru Healthcare manages the Consumer Health / Medical Devices Division, which is focused on commercializing sexual healthcare products and devices for the consumer market, including the Company's FC2 Female Condom^® (now available by prescription) in the consumer health products sector and PREBOOST^® medicated individual wipe, which is a male genital desensitizing drug product that helps in the prevention of premature ejaculation.
   
• The Female Health Company manages the Global Public Health Division, which is focused on the global public health sector FC2 business.  This division markets the Company’s Female Condom (FC2) to entities, including ministries of health, government health agencies, U.N. agencies, nonprofit organizations and commercial partners, that work to support and improve the lives, health and well-being of women around the world.

More information about the Female Health Company and its products can be found at www.fc2femalecondom.com.  For corporate and investor-related information about the Company, please visit https://veruhealthcare.com/investors.

Contact:
Kevin Gilbert: 312-366-2633